{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:22:16Z","timestamp":1790472136865,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.lpm.2006.12.019","type":"journal-article","created":{"date-parts":[[2008,1,26]],"date-time":"2008-01-26T05:54:08Z","timestamp":1201326848000},"page":"333-340","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["Place actuelle des\u00a0inhibiteurs de\u00a0l'aromatase dans\u00a0le\u00a0traitement adjuvant des\u00a0cancers du\u00a0sein"],"prefix":"10.1016","volume":"36","author":[{"given":"Jean-Pierre","family":"Bergerat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2006.12.019_bib1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2006.12.019_bib2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1212\/01.WNL.0000140491.54664.50","article-title":"Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis","volume":"63","author":"Bushnell","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2006.12.019_bib3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/jnci\/djh285","article-title":"Stroke risk and tamoxifen therapy for breast cancer","volume":"96","author":"Geiger","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lpm.2006.12.019_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2006.12.019_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"The","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.lpm.2006.12.019_bib6","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"10.1016\/j.lpm.2006.12.019_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.breast.2006.01.004","article-title":"The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98","volume":"15","author":"Monnier","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.lpm.2006.12.019_bib8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2006.12.019_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 7","key":"10.1016\/j.lpm.2006.12.019_bib10","doi-asserted-by":"crossref","first-page":"vii10","DOI":"10.1093\/annonc\/mdl941","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"17","author":"Boccardo","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lpm.2006.12.019_bib12","first-page":"10s","article-title":"Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a","volume":"23","author":"Jakesz","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib13","doi-asserted-by":"crossref","first-page":"LBA527","DOI":"10.1200\/jco.2006.24.18_suppl.lba527","article-title":"First mature analysis of the Intergroup Exemestane Study","volume":"24","author":"Coombes","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib14","first-page":"10","article-title":"Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG trial8, and the ITA trial","volume":"94","author":"Jonat","year":"2005","journal-title":"Br Cancer Res Treat."},{"key":"10.1016\/j.lpm.2006.12.019_bib15","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","article-title":"Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women","volume":"23","author":"Whelan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2006.12.019_bib16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","article-title":"Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer","volume":"24","author":"Fallowfield","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lpm.2006.12.019_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.bjc.6602964","article-title":"Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?","volume":"94","author":"Cuzick","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lpm.2006.12.019_bib18","doi-asserted-by":"crossref","first-page":"1049s","DOI":"10.1158\/1078-0432.CCR-05-2123","article-title":"Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial","volume":"12","author":"Hilsenbeck","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2006.12.019_bib19","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1200\/JCO.2005.02.964","article-title":"Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis","volume":"23","author":"Punglia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib20","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib21","article-title":"Optimal duration of adjuvant tamoxifen in early breast cancer: ten year results or a randomized trial of the FNCLCC Breast Group","volume":"94","author":"Delozier","year":"2005","journal-title":"Breast Cancer Res and Treatment"},{"key":"10.1016\/j.lpm.2006.12.019_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-006-9207-y","article-title":"Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial","volume":"99","author":"Ingle","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 7","key":"10.1016\/j.lpm.2006.12.019_bib23","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminoncol.2006.03.025","article-title":"Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial","volume":"33","author":"Goss","year":"2006","journal-title":"Semin Oncol"},{"issue":"18","key":"10.1016\/j.lpm.2006.12.019_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2005.01.1304","article-title":"Cognitive impairment, aromatase inhibitors, and age","volume":"23","author":"Tralongo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2006.12.019_bib26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.breast.2005.08.021","article-title":"Predicting response to systemic treatments: learning from the past to plan for the future","volume":"14","author":"Regan","year":"2005","journal-title":"Breast"},{"key":"10.1016\/j.lpm.2006.12.019_bib27","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","article-title":"Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases","volume":"21","author":"Bardou","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib28","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2005.01.4829","article-title":"Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study","volume":"23","author":"Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib29","article-title":"Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer","volume":"94","author":"Viale","year":"2005","journal-title":"Breast Cancer Res and Treatment"},{"key":"10.1016\/j.lpm.2006.12.019_bib30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.breast.2005.08.024","article-title":"Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy","volume":"14","author":"Osborne","year":"2005","journal-title":"Breast"},{"key":"10.1016\/j.lpm.2006.12.019_bib31","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1200\/JCO.2005.09.004","article-title":"Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy","volume":"23","author":"Cui","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jnci\/dji249","article-title":"Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance","volume":"97","author":"Arpino","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lpm.2006.12.019_bib33","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2006.12.019_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib35","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1677\/erc.1.01005","article-title":"Epidermal growth factor receptor\/HER2\/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer","volume":"12","author":"Gee","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lpm.2006.12.019_bib36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1677\/erc.1.00857","article-title":"Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lpm.2006.12.019_bib37","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1158\/1078-0432.CCR-04-2569","article-title":"A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer","volume":"11","author":"De Laurentiis","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2006.12.019_bib38","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2005.07.559","article-title":"Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists","volume":"23","author":"Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib39","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial","volume":"19","author":"Ellis","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib40","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1200\/JCO.2000.18.20.3471","article-title":"HER-2\/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer","volume":"18","author":"Berry","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib41","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2001.19.14.3376","article-title":"Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients","volume":"19","author":"Knoop","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib42","first-page":"1039","article-title":"Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer","volume":"9","author":"De Placido","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2006.12.019_bib43","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1023\/A:1008313310474","article-title":"ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer","volume":"11","author":"Stal","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2006.12.019_bib44","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1078-0432.CCR-1060-02","article-title":"Synergistic interactions between tamoxifen and trastuzumab (Herceptin)","volume":"10","author":"Argiris","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2006.12.019_bib45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00520-006-0035-8","article-title":"Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis","volume":"14","author":"Rocchi","year":"2006","journal-title":"Support Care Cancer"},{"issue":"suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib46","article-title":"Does everyone need letrozole after 5 years' tamoxifen and breast conservation","volume":"88","author":"Cameron","year":"2004","journal-title":"Breast Cancer Res and Treatment"},{"key":"10.1016\/j.lpm.2006.12.019_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.514","article-title":"ER+ PR- breast cancer defines a unique subtype of breast cancer tahat is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies","author":"Finn","year":"2006","journal-title":"Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib48","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10549-005-9038-2","article-title":"Life following aromatase inhibitors--where now for endocrine sequencing?","volume":"93","author":"Johnston","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.lpm.2006.12.019_bib49","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1677\/erc.1.00905","article-title":"The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling","volume":"12","author":"Martin","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2006.12.019_bib50","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s10549-005-9037-3","article-title":"Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance","volume":"93","author":"Dowsett","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.lpm.2006.12.019_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.515","article-title":"Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenoapusal women, with ER\/PgR+ breast cancer (Study 223)","author":"Dowsett","year":"2006","journal-title":"Am Soc Clin Oncol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498206001783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498206001783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T03:18:31Z","timestamp":1684207111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498206001783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0755498206001783"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2006.12.019","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}